Overview

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Rituximab